
company:hims
HIMS ends compounded Semaglutide offering
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
company:hims
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
chemical:semaglutide
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
country:mexico
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:watercooler
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.
category:watercooler
We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.
Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.
A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.